Markets › India › NSE › AUROPHARMA

Aurobindo Pharma Ltd

NSE:AUROPHARMAHealthcareNSE:CNX200NSE:CNX500

₹1,621.40−2.73%At closeAt close · Mon 19 Oct · ≈ AED 62.56 · Market cap $10.03B · Next earnings Mon 9 Nov

Ratio	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	Current · undated	YoY
Gross margin	58.9%	55.4%	53.2%	55.2%	57.5%	39.2%	—	—
Operating margin	38.0%	33.3%	32.6%	36.0%	37.8%	15.1%	15.1%	+0.0 pts
Net margin	21.5%	11.3%	7.8%	10.9%	11.0%	10.4%	10.4%	+0.0 pts
EBITDA margin	21.8%	18.4%	14.6%	19.9%	20.3%	21.6%	—	—
Return on equity	24.3%	10.8%	7.2%	10.6%	10.7%	9.2%	9.3%	+0.0 pts
Return on assets	15.8%	7.8%	4.8%	7.0%	7.0%	6.0%	6.0%	+0.0 pts
Return on capital employed	40.6%	30.3%	28.5%	31.8%	34.2%	12.5%	—	—
Debt / equity	0.2×	0.1×	0.2×	0.2×	0.3×	0.2×	0.2×	+0.0%
Debt / assets	15.8%	9.7%	13.3%	14.7%	16.6%	13.8%	—	—
Interest coverage	126.2×	160.5×	57.7×	36.1×	26.2×	13.2×	—	—
Current ratio	1.9×	2.2×	1.9×	2.0×	1.9×	1.8×	1.8×	+0.0%
Quick ratio	1.0×	1.3×	1.1×	1.2×	1.1×	1.1×	—	—
Cash ratio	0.5×	0.5×	0.4×	0.3×	0.6×	0.5×	0.5×	+0.0%
Asset turnover	0.7×	0.7×	0.6×	0.6×	0.6×	0.6×	—	—
Inventory turnover	1.1×	1.4×	1.4×	1.3×	1.3×	1.7×	—	—
Receivables turnover	6.2×	5.3×	5.6×	6.0×	5.5×	4.7×	—	—
Dividend payout	4.4%	10.0%	22.8%	8.3%	0.0%	6.6%	—	—

Margins, returns, leverage and liquidityUpdated Tue 31 Mar ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.